Similarly, plasma PTX3 may be also useful for targeted therapy against fibrosis in NASH patients, because in our study, the plasma PTX3 level was found to be more significantly elevated in the advanced stages of NAFLD patient. This evidence concerns the gene PTX3 and metabolic dysfunction-associated steatohepatitis.